high
2025-07-14 10:00:02
2025 National Reimbursement Drug List Adjustment Launched, Greater Support for 'Genuine Innovation'
2025年医保目录调整启动 支持“真创新”力度更大
深圳市发展和改革委员会
fgw
This document announces the launch of the 2025 adjustment process for China's National Reimbursement Drug List (NRDL), emphasizing a strengthened focus on including and supporting genuinely innovative pharmaceuticals.
Document Text
Body text not yet extracted. View on original site
Topics
healthcare policy
pharmaceutical regulation
drug pricing
Metadata
| Publisher | 深圳市发展和改革委员会 |
| Site | fgw |
| Date | 2025-07-14 10:00:02 |
| Category | report |
| Policy Area | 医疗保障 |
| CMS Category | 工作动态 |
Verification